Nektar Therapeutics
Nasdaq · Healthcare · Pharmaceutical Preparations · San Francisco, CA
NKTR chart
What traders are saying about $NKTR
Latest postsNektar Therapeutics news
- Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga
The National Law Review ·
- Nektar Therapeutics stock fell 3.70 percent on Nasdaq on October 23, 2026
ad-hoc-news.de ·
- Nektar Therapeutics Stock Price Forecast. Should You Buy NKTR?
StockInvest.us ·
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Price performance
Yahoo Finance UK ·
- Nektar Therapeutics (NasdaqCM:NKTR) Stock Forecast & Analyst Predictions
Simply Wall Street ·
- Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?
Yahoo Finance ·
- Nektar Therapeutics (NKTR) Could Be 71% Undervalued As Rezpegaldesleukin Data Extend Its Case
Yahoo Finance ·
- Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang
Yahoo Finance ·
- EADV26: Key late-stage readouts from the conference
clinicaltrialsarena.com ·
- Nektar Posted Promising Alopecia Results. Here's Why It Took A 22% Beating.
Yahoo Finance ·
- NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge
stocktwits.com ·
Nektar Therapeutics key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $55.2M | $98.4M | $90.1M | $92.1M |
| Net income | -$164.0M | -$119.0M | -$276.0M | -$368.0M |
| Diluted EPS | $-9.73 | $-8.68 | $-1.45 | $-1.97 |
| Total assets (year end) | $280.4M | $303.9M | $398.0M | $710.6M |
| Cash and equivalents (year end) | $15.1M | $44.3M | $35.3M | $88.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 10-Q10-Q
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 8-K8-K
- 10-Q10-Q
- 8-KCURRENT REPORT
- DEF 14ADEF 14A
- 8-K8-K
- 8-K8-K
About Nektar Therapeutics
- Ticker
- NKTR (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- San Francisco, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 906709
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
Frequently asked questions
What exchange is Nektar Therapeutics listed on?
Nektar Therapeutics trades on the Nasdaq under the ticker symbol NKTR.
What industry is Nektar Therapeutics in?
Nektar Therapeutics is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Nektar Therapeutics headquartered?
Nektar Therapeutics's business address on file with the SEC is in San Francisco, CA.
When does Nektar Therapeutics's fiscal year end?
Nektar Therapeutics's fiscal year ends on December 31.
How much revenue did Nektar Therapeutics report?
Nektar Therapeutics reported $55.2M in revenue for calendar year 2025, according to its SEC filings.